FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata

FDA approval expands Olumiant use to U.S. adolescents with severe alopecia areata.

What the company is saying

Eli Lilly and Company (NYSE:LLY) is announcing that the FDA has approved Olumiant (baricitinib) for pediatric patients aged 12 and older with severe alopecia areata (AA), expanding its U.S. label beyond adults. The company frames this as a major milestone for adolescents and their families, emphasizing the lack of prior treatment options and the impact of AA during adolescence. Adrienne Brown, executive vice president and president of Lilly Immunology, highlights the importance of this approval for young patients. The release stresses the robustness of the supporting data, citing BRAVE-AA-PEDS as the first and largest Phase 3 study for this population. The company underscores Olumiant’s established safety profile, its availability in multiple tablet strengths, and its existing coverage by major pharmacy benefit managers. Lilly also points to over 33,000 U.S. patients prescribed Olumiant since 2017, reinforcing its market presence. The announcement is confident, data-driven, and positions Olumiant as a leading systemic therapy for severe AA in both adults and adolescents.

What the data suggests

The FDA approval is supported by 36-week data from the BRAVE-AA-PEDS Phase 3 trial, which included 257 adolescents in the first cohort and 166 in the second. At baseline, the median Severity of Alopecia Tool (SALT) score was 100, indicating complete scalp hair loss, with patients having a mean disease duration of 6.4 years. At week 36, 42% of patients treated with Olumiant 4 mg and 27% with 2 mg achieved at least 80% scalp hair coverage (SALT ≤20), compared to 5% on placebo. For 90% or more scalp hair coverage (SALT ≤10), 37% on 4 mg and 21% on 2 mg responded, versus 2% on placebo. Improved eyebrow and eyelash coverage was observed in patients with baseline loss treated with 4 mg, though no specific numbers are given. The safety profile in adolescents matches that seen in adults. Since 2017, more than 33,000 U.S. patients have been prescribed Olumiant. The product is already approved for severe AA in adults and adolescents in the U.S., EU, and Japan. No financial metrics or sales projections are disclosed.

Analysis

The announcement's tone is positive but proportionate to the measurable progress disclosed. The key claim is the FDA approval of Olumiant for pediatric patients with severe alopecia areata, which is a realised regulatory milestone, not a forward-looking projection. The release provides detailed, quantitative clinical trial results (e.g., 42% of patients on 4 mg achieved 80%+ scalp hair coverage at 36 weeks), supporting the efficacy claims. While some forward-looking statements about commitment to patient access and advancing care are present, these are generic and do not inflate the signal. There is no mention of large capital outlays or long-dated, uncertain returns; the benefits of the approval are immediate, as the product is already available. The absence of financial metrics (revenue, profit) limits the signal to weak_positive, per the Disclosure Completeness Rule, but there is no exaggeration or narrative inflation relative to the evidence.

Risk flags

• ●Olumiant’s U.S. label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. These risks are material and could limit uptake or lead to adverse outcomes in real-world use.
• ●No quantitative safety data for the pediatric cohort is disclosed, making it difficult to independently assess the risk-benefit profile for this new population beyond the statement of consistency with adult safety data.
• ●The announcement does not provide any financial projections or estimates of incremental revenue or market size attributable to this label expansion, leaving the commercial impact uncertain.
• ●AA is a chronic and unpredictable disease, and the clinical trial population had a mean disease duration of 6.4 years with complete scalp hair loss at baseline; real-world effectiveness and adherence may differ from trial results.
• ●While Olumiant is covered by major pharmacy benefit managers for adults, the announcement does not specify the extent of pediatric coverage or potential reimbursement challenges for the new indication.

Bottom line

This FDA approval allows Eli Lilly’s Olumiant to be prescribed immediately to U.S. adolescents aged 12 and older with severe alopecia areata, addressing a significant unmet need. The clinical data show that 42% of patients on 4 mg and 27% on 2 mg achieved at least 80% scalp hair coverage at 36 weeks, with strong placebo separation. The safety profile is said to match that in adults, but no detailed pediatric safety numbers are given, and the product carries a boxed warning for serious adverse events. Over 33,000 U.S. patients have already been prescribed Olumiant, demonstrating established market presence, but the company provides no financial guidance or revenue estimates for this new population. The immediate commercial impact will depend on real-world uptake, payer coverage, and safety outcomes in adolescents. Investors should focus on post-launch prescription trends, any emerging safety signals, and future disclosures on pediatric market penetration. The key takeaway is that Lilly has secured a rapid, label-expanding regulatory win with robust efficacy data but leaves the financial upside and risk profile only partially quantified.

Announcement summary

(NYSE:LLY) Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). This approval expands Olumiant's U.S. label, which already included adults with moderately to severely active rheumatoid arthritis and severe AA. As many as 2% of people develop AA at some point in their lives, and nearly 40% of cases occur before the age of 20. The FDA approval is based on 36-week data from the adolescent cohort (ages 12 to under 18) of BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe AA. At baseline, the median Severity of Alopecia Tool (SALT) score was 100, indicating complete scalp hair loss, and patients had been living with AA for a mean of 6.4 years. At Week 36, 42% of patients treated with Olumiant 4 mg and 27% treated with Olumiant 2 mg achieved 80% or more scalp hair coverage (SALT score ≤ 20), compared with 5% receiving placebo. 37% of patients treated with Olumiant 4 mg and 21% treated with Olumiant 2 mg achieved 90% or more scalp hair coverage (SALT score ≤ 10), compared with 2% receiving placebo. Improved eyebrow and eyelash coverage was observed among patients with substantial eyebrow and eyelash hair loss at baseline treated with Olumiant 4 mg. The overall safety profile observed in pediatric patients 12 years of age and older with severe AA is consistent with the safety profile in adults with severe AA. The U.S. FDA-approved labeling for Olumiant includes a boxed warning for risk of serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Olumiant is available as 4 mg, 2 mg, and 1 mg tablets. The recommended dose is Olumiant 2 mg/day, with an increase to 4 mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, treatment with 4 mg/day may be considered, and once an adequate response is achieved, the dosage is to be decreased to 2 mg/day. Since 2017, more than 33,000 patients have been prescribed Olumiant in the U.S. Olumiant was discovered by Incyte and licensed to Lilly. In April 2026, the European Commission approved Olumiant for the treatment of adolescents (ages 12 to under 18) with severe AA. BRAVE-AA-PEDS (NCT05723198) is an ongoing, placebo-controlled, Phase 3 clinical trial involving pediatric patients ages 12 to under 18 years with severe AA, as measured by a SALT score of ≥50 and a current episode of severe AA lasting at least six months but no more than eight years. The first cohort included 257 adolescent participants randomized in a 1:1:1 ratio to receive once-daily placebo, Olumiant 4 mg, or Olumiant 2 mg. The primary endpoint was a SALT score ≤20 at Week 36. The second cohort of 166 adolescents was randomized 1:1 to Olumiant 4 mg or Olumiant 2 mg to further accumulate safety data. Olumiant is approved in the U.S. and more than 75 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. Olumiant is also approved for adults and pediatric patients 12 years of age and older with severe AA in the US, European Union, and Japan. Olumiant is also approved for the treatment of hospitalized adults with COVID-19 in the U.S. In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of Olumiant and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

Disagree with this article?